Advanced Therapeutic Strategies and Family Planning for Women with Multiple Sclerosis

Program Overview

This program is derived from content presented at the Consortium of Multiple Sclerosis Centers (CMSC) 34^th Annual Meeting. This CME/CE activity will highlight advanced therapeutic strategies and family planning best practices for women with multiple sclerosis (MS). The expert faculty, led by Dr. Fred D. Lublin, will analyze the immunopathology, epidemiology, and immune therapeutic targets for MS. Recent clinical trial data and current therapies for the effective treatment of women with multiple sclerosis through their child-bearing years will be reviewed. The expert faculty will conclude with a review of the vital role that the interprofessional team plays in educating and caring for women of child-bearing age who have MS.

Target Audience

Healthcare professionals who care for patients with MS, including neurologists, primary care physicians, obstetricians/gynecologists, PAs, NPs, RNs, nurse educators and pharmacists

Agenda

1. Welcome and Introductions – Fred D. Lublin, MD
2. Immuno-pathology, Epidemiology, and Immune Therapeutic Targets for Multiple Sclerosis – Scott Douglas Newsome, DO
3. Current Practice and Clinical Trial Analysis for the Safe and Effective Treatment of Women with MS throughout the Child-bearing Years – Amy Perrin Ross, APN, MSN, CNRN, MSCN
4. The Role of the Essential Interprofessional Team to Educate and Care for Women of Child-bearing Age who have MS – Kathleen Costello, MS, ANP-BC, MSCN
5. Interactive Panel Discussion – Fred D. Lublin, MD and Expert Faculty

Learning Objectives

1. Explain the epidemiology, immunopathology, and immune therapeutic targets for MS
2. Analyze current practice and clinical trial data for the safe and effective treatment of women with MS, and the implications for family planning, including preconception, pregnancy, and post-partum settings
3. Optimize the interprofessional team to educate and provide care for women of child-bearing age who have MS

Faculty

Fred D. Lublin, MD (Course Chair)
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York

Kathleen Costello, MS, ANP-BC, MSCN
Vice-President, Healthcare Access
National Multiple Sclerosis Society
John Hopkins Multiple Sclerosis Center
Baltimore, Maryland

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Neuroscience Program Coordinator
Loyola University Medical Center
Maywood, Illinois

Scott Douglas Newsome, DO
Director, Neurosciences Consultation and Infusion Center at Green Spring Station
Director, Stiff Person Syndrome Center
Co-Director, Multiple Sclerosis Experimental Therapeutics Program
Director, Optical Coherence Tomography Clinic
Associate Professor of Neurology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Fred D. Lublin, MD (Course Chair)
Consultant/Advisor: Actelion Pharmaceuticals Ltd; Apitope; Atara Biotherapeutics, Inc.; Biogen; BrainStorm Cell Limited; Celgene Corporation: A Bristol-Myers Squibb Company; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GW Pharmaceuticals; Innate Immunotherapeutics; Jazz Pharmaceuticals; Orion Biotechnology Canada, Ltd.; Polpharma; Population Council; Receptos Inc.; Sanofi Genzyme; Teva Pharmaceutical Industries Ltd.; TG Theraputics
Grant/Research Support:  Actelion Pharmaceuticals Ltd; Biogen; BrainStorm Cell Limited; Novartis; Sanofi Genzyme
Speaker’s Bureau: Sanofi Genzyme

Kathleen Costello, MS, ANP-BC, MSCN
Nothing to disclose

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Consultant/Advisor: Alexion Pharmaceuticals; Biogen; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Mallinckrodt Pharmaceuticals; Novartis; Sanofi Genzyme; Veil Bio
Speaker’s Bureau: Alexion Pharmaceuticals; Biogen; EMD Serono, Inc.; Genentech, Inc.; Mallinckrodt Pharmaceuticals; Novartis; Sanofi Genzyme

Scott Douglas Newsome, DO
Consultant/Advisor: Biogen; BioIncept, LLC.; EMD Serono, Inc.; Genentech, Inc.; MedDay Pharmaceuticals

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Charles Pollack, MD, MA; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.